Use of IGIV in the Treatment of Immune-Mediated Dermatologic Disorders

Journal of Investigative Dermatology Symposium Proceedings

Volumn 9, Issue 1, 2004, Pages 92-96

  Gelfand, Erwin W ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Anti inflammatory immunomodulatory; Determatology; IGIV

Indexed keywords

CORTICOSTEROID; CYTOTOXIC AGENT; IMMUNOGLOBULIN;

ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; CLINICAL TRIAL; CONFERENCE PAPER; DERMATOMYOSITIS; GRAFT VERSUS HOST REACTION; HUMAN; HYPERIMMUNOGLOBULINEMIA E; IMMUNOMODULATION; PEMPHIGUS; PYODERMA GANGRENOSUM; SCLERODERMA; SKIN DISEASE; STEVENS JOHNSON SYNDROME; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VALIDATION PROCESS;

EID: 0346040477     PISSN: 10870024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1087-0024.2004.00834.x     Document Type: Conference Paper

References (58)

1. Ahmed AR: Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 45:825-835, 2001b
2. Ahmed AR: Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 45:679-690, 2001a
3. Ahmed AR, Sami N: Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol 46:42-49, 2002
4. Amagal M: Adhesion molecules. I. Keratinocyte-keratinocyte interactions. Cadherin and pemphigus. 104:146-152, 1995
5. Anderson U, Bjork L, Skansen-Saphir U, Andersson J: Pooled human IgE modulates cytokine production in lymphocytes and monocytes. Immunol Rev 139:21-42, 1984
6. Arend WP, Leung DY: IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev 139:71-78, 1994
7. Aukrust P, Froland SS, Liabakk NB, et al: Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84:2136-2143, 1994
8. Bewley AP, Keefe M: Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Br J Dermatol 135:128-129, 1996
9. Bystryn J-C, Jiao D, Natow S: Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 47:358-363, 2002
10. Campbell DE, Georgiou GM, Kemp AS: Pooled human immunoglobulin inhibits IL-4 but not IFN-γ or TNF-α secretion following in vitro stimulation of mononuclear cells with staphylococcal superantigen. Cytokine 11:359-385, 1999
11. Collet E, Dalac S, Maerena B, Courtois JM, Izac M, Lambert D: Juvenile dermatomyositis: Treatment with intravenous gammaglobulin. Br J Dermatol 130: 231-234, 1994
12. Colonna L, Gianchini G, Frezzolini A, De Pila O, Di Lella G, Puddu P: Intravenous immunoglobulin for pemphigus vulgari: Adjuvant or first choice therapy? Br J Dermatol 138:1102-1103, 1998
13. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. New Engl J Med 329:1993-2000, 1993
14. Engineer L, Ahmed AR: Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: Analysis of current data. J Am Acad Dermatol 44:83-88, 2001
15. Engineer L, Bhol KC, Ahmed AR: Analysis of current data on the use of intravenous immunoglobulin in management of pemphigus vulgaris. J Am Acad Dermatol 43:1049-1057, 2000
16. Enk AH, Knop J: Adjuvant therapy of pemphigus vulgaris and pemphigus foliaceus with intravenous immunoglobulins. Haurarzt 49:774-776, 1998
17. Fehr J, Hoffmann V, Kappelar U: Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high dose intravenous gamma globulin. N Engl J Med 306:1254-1258, 1982
18. Furuya Y, Takahashi T, Hamamoto H, Nishimura M, Kawakami Y: High-dose immunoglobulin therapy for a patient with dermatomyositis. Intern Med 37: 642-645, 1998
19. Gelfand EW: Intravenous gammaglobulin therapy in immunocompromised patients. In: Garner RJ, Sacher RA (eds). Intravenous Gammaglobulin Therapy. Arlington, VA: American Association of Blood Banks, 1988; p 31-46
20. Gelfand EW, Landwehr LP, Esterl B, Mazer B: Intravenous immunoglobulin: An alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol 104:61-66, 1996
21. Harman KE, Black MM: High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: An evaluation of its use in 14 cases. Br J Dermatol 140:865-874, 1999
22. Hen S, Harman K, Bhogal BS, Black MM: A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulins and cyclosporin. Clin Exp Dermatol 23:185-188, 1998
23. Hurez V, Kaveri SV, Mouhoub A, et al: Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (intravenous immunoglobulin, IVIG). Ther Immunol 1:269-278, 1994
24. Imbach P, Barandun S, diApuzzo V, et al: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228-1231, 1981
25. Ipp MM, Gelfand EW: Antibody deficiency and alopecia. J Ped 89:728-731, 1976
26. Jolles S, Hughes J, Rustin M: Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis. J Am Acad Dermatol 40:121-123, 1999
27. Kaveri S, Vassilev T, Hurez V, et al: Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use (IVIG). J Clin Invest 97:865-869, 1996
28. Kazatchkine MD, Dietrich G, Hurez V, et al: V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIG). Immunol Rev 139: 79-107, 1994
29. Kazatchkine MD, Kaveri SV: Advances in immunology. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. New Engl J Med 345:747-755, 2001
30. Khan IU, Bhol KC, Ahmed AR: Linear IgA bullous dermatosis in a patient with chronic renal failure: Response to intravenous immunoglobulin therapy. J Am Acad Dermatol 40:485-488, 1999
31. Koller H, Wambacher-Gasser B, Topar G, et al: Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita. J Am Acad Dermatol 36:331-335, 1997
32. Kroiss MM, Vogt T, Landthaier M, Stotz W: High-dose intravenous immune globulin is also effective in linear IgA diseases. Br J Dermatol 142:582, 2000
33. Kumari S, Bhol KC, Rehman F, Foster CS, Ahmed AR: Interleukin 1 components in cicatricial pemphigoid: Role in intravenous immunoglobulin therapy. Cytokine 14:218-224, 2001
34. Letko E, Bhol KC, Foster CS, Ahmed AR: Influence of intravenous immunoglobulin therapy on serum levels of anti-β4 antibodies in ocular cicatricial pemphigoid. Current Eye Res 21:646-654, 2000
35. Leung DYM, Spahn JD, Szefler SJ: Steroid-unresponsive asthma. In: Kraft M (ed). Chapter for Seminars Respiratory Critical Care Medicine. New York: Thieme Medical Publishers, 2002; p 387-398
36. Messer G, Sizmann N, Feucht H, Meurer M: High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris. Br J Dermatol 133: 1014-1016, 1995
37. Modiano JF, Amran D, Lack G, Bradley K, Ball C, Domenico J, Gelfand EW: Posttranscriptional regulation of T cell IL-2 production by human pooled immunoglobulin. Clin Immunol Immunopath 83:77-85, 1997
38. Mohr C, Sunderkotter C, Hildebrand A, et al: Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol 132: 824-826, 1995
39. Prasad N, Papoff G, Zeuner A, et al: Therapeutic preparations of normal polyspecific immunoglobulin G (IVIG) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIG involving the Fas apoptotic pathway. J Immunol 161:3781-3790, 1998
40. Roifman CM, Schaffer FM, Wachsmuth SE, Murphy G, Gelfand EW: Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 258:513-515, 1987
41. Rossi F, Dietrich G, Kazatchkine MD: Anti-idiotypes against autoantibodics in normal immunoglobulins. Evidence for network regulation of human autoimmune responses. Immunol Rev 110:135-149, 1989
42. Ruetter A, Luger TA: High-dose intravenous immunoglobulins. An approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol 44:1010-1024, 2001
43. Ruetter GH, Sunderkotter C, Ruetter A, et al: Intravenous immunglobuline, sin wirksames und gut vartragliches additivum in der behandling theraplerasistantar autoimmundermatosen. In: Macher E, Kolde G, Brocker EB (eds). Tumoran und Haut, Jahrbuch der Dermatologie. Germany: Blermann-Verlag, 1994; p 275-288
44. Sabroe RA, Wallington TB, Kennedy CT: Dermatomyositis treated with high-dose intravenous immunoglobulins and associated with panniculitis. Clin Exp Dermatol 20:164-167, 1995
45. Sami N, Bhol KC, Ahmed AR: Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titers to human alpha 6 integrin. Clin Exp Immunol, in press
46. Sami N, Qureshi A, Ahmed AR: Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus. Eur J Dermatol 12:174-178, 2002
47. Samuelsson A, Towers TL, Ravetch JV: Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484-486, 2001
48. Shimizu H, McDonald JN, Gunner DB, et al: Epidermolysis bullosa acquisita antigen and the carboxy-terminus of type VII collagen have a common immunolocalization to anchoring fibrils and lamina densa of basement membrane. Br J Dermatol 122:577-585, 1990
49. Shimozato T, Iwata M, Kawada H, Tamura N: Human immunoglobulin prepared for intravenous use induces elevation of cellular cyclic adenosine 3í-5í-monophosphate levels, resulting in suppression of tumor necrosis factor α and interleukin-1 production. Immunology 72:497-501, 1991
50. Spahn JD, Leung DYM, Chan MTS, Szefler SJ, Gelfand EW: Mechanisms of glucocorticoid reduction in asthmatics treated with intravenous immunoglobulin. J Allergy Clin Immunol 103:421-426, 1999
51. Stanley JR: Update. Structure and function of pemphigus vulgaris antigen. J Dermatol 24:741-743, 1997
52. Stuckey M, Quinn PA, Gelfand EW: Identification of ureaplasma urealyticum (T-stain mycoplasma) in a patient with polyarthritis. Lancet 2:917-920, 1978
53. Takei S, Arora YK, Walker SM: Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 91:602-607, 1993
54. Thivolet J: Pemphigus: Past, present, and future. Dermatology 189:26-29, 1994
55. Tsujimoto H, Takeshita S, Nakatani K, Kawamura Y, Tokutomi T, Sekine I: Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease. Clin Immunol 103:161-168, 2002
56. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490-493, 1998
57. Weaver S, Zillkens D, Brocker EB: Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy. Br J Dermatol 135:862-863, 1996
58. Yu Z, Lennon VA: Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. New Engl J Med 340:227-228, 1999